advanced hcc: treatment options for patients ineligible for io - patient case video
Published 3 months ago • 70 plays • Length 5:13Download video MP4
Download video MP3
Similar videos
-
15:56
patients with advanced hcc not eligible for io in 1st line
-
14:53
overview of 2nd line treatment options in advanced hcc
-
29:27
a new era in treating patients with advanced hcc: 2nd line treatment selection and when to switch?
-
3:49
update from esmo 2024: immunotherapy (io) for hcc
-
0:52
curative and palliative treatment options for patients with hepatocellular carcinoma
-
5:57
treatment options for locally advanced hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
3:55
the use of immunotherapy in hcc – efficacy and safety
-
4:21
the use of immunotherapy in hcc – in depth subgroup analyses and challenges
-
24:30
reviewing the outcomes in hcc with 1st line immunotherapy: when is the right time to switch?
-
10:14
ruptured large hepatocellular carcinoma - management - long term survival - edusurg clinics
-
34:21
the hcc treatment algorithm: new and emerging monotherapy, combination, and multimodal approaches
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
1:16
assessing treatment options for hepatocellular carcinoma
-
17:55
hepatocellular carcinoma: medical treatment
-
2:14
examining standard radiation treatments for the long-term management of hcc
-
1:37:24
evidence-based treatment selection and sequencing in advanced hcc
-
35:53
update on initial management of advanced hcc